When Maegan collapsed on a playground at age seven, her family entered a decade of medical uncertainty. Now, her twin sister Claire, a neuroscientist at the University of Oxford, has identified an antibody that may offer new hope for those living with CIDP.
The cycle of misdiagnosis from Charcot-Marie-Tooth to Guillain-Barré
Maegan Bergstrom Johnson's struggle with neurological health began with a sudden collapse in a school sandpit. what started as a moment of physical instability quickly spiraled into a decade of medical confusion and incorrect diagnoses.
According to the report, medical professionals initially misidentified her symptoms as Charcot-Marie-Tooth disease. This error delayed proper treatment while Maegan experienced escalating muscle weakness and severe pain. The situation worsened when a subsequent referral to the Mayo Clinic led dotors to diagnose her with Guillain-Barré syndrome, a mistake that saw her hospitalized and eventually left her wheelchair-bound.
The family's experience highlights a recurring issue in rare disease management: the difficulty of distinguishing between similar-looking neurological disorders. For the Bergstrom Johnson family, the path to a correct diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) only came after Maegan's condition had already caused significant, permanent physical deterioration.
Claire Bergstrom Johnson’s antibody discovery at the University of Oxford
Claire Bergstrom Johnson has transitioned from a witness to her sister's decline to a leading figure in the fight against the disease. Now working as a neuroscientist at Oxford University, Claire has identified a specific antibody that could serve as the foundation for new CIDP therapies.
This discovery represents a shift from managing symptoms to potentially targeting the underlying autoimmune mechanism of the disease. As the report states, the identification of this antibody offers a potential pathway toward treatments that were previously unavailable to patients like Maegan .
A potential lifeline for 5,000 people in the UK
The discovery arrives at a critical time for the neurological community in the United Kingdom. Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune condition that currently affects roughly 5,000 people across the country,none of whom have access to a definitive cure.
Because CIDP involves the immune system attacking the protective sheath of nerves, the physical toll can be devastating, leading to parlysis and loss of motor function. For the thousands of UK residents living with this condition, Claire Bergstrom Johnson's research at the University of Oxford could mean the difference between progressive disability and managed health.
The gap between antibody discovery and clinical trials
While the identification of the antibody is a landmark achievement, the report does not specify the timeline for clinical application or the potential side effects of the treatment. It remains unknown whether this discovery will lead to a single targeted drug or a broader class of immunosuppressive therapies, leaving questions about how effectively this antibody can be synthesized for widespread human use.
Comments 0